𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gene therapy for pain: Results of a phase I clinical trial

✍ Scribed by David J. Fink; James Wechuck; Marina Mata; Joseph C. Glorioso; James Goss; David Krisky; Darren Wolfe

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
235 KB
Volume
70
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective:

Preclinical evidence indicates that gene transfer to the dorsal root ganglion using replication‐defective herpes simplex virus (HSV)‐based vectors can reduce pain‐related behavior in animal models of pain. This clinical trial was carried out to assess the safety and explore the potential efficacy of this approach in humans.

Methods:

We conducted a multicenter, dose‐escalation, phase I clinical trial of NP2, a replication‐defective HSV‐based vector expressing human preproenkephalin (PENK) in subjects with intractable focal pain caused by cancer. NP2 was injected intradermally into the dermatome(s) corresponding to the radicular distribution of pain. The primary outcome was safety. As secondary measures, efficacy of pain relief was assessed using a numeric rating scale (NRS), the Short Form McGill Pain Questionnaire (SF‐MPQ), and concurrent opiate usage.

Results:

Ten subjects with moderate to severe intractable pain despite treatment with >200mg/day of morphine (or equivalent) were enrolled into the study. Treatment was well tolerated with no study agent‐related serious adverse events observed at any point in the study. Subjects receiving the low dose of NP2 reported no substantive change in pain. Subjects in the middle‐ and high‐dose cohorts reported pain relief as assessed by NRS and SF‐MPQ.

Interpretation:

Treatment of intractable pain with NP2 was well tolerated. There were no placebo controls in this relatively small study, but the dose‐responsive analgesic effects suggest that NP2 may be effective in reducing pain and warrants further clinical investigation. ANN NEUROL 2011

📜 SIMILAR VOLUMES

Gene transfer and therapy clinical trial
Gene transfer and therapy clinical trials – update. Part I: Countries, Diseases, Clinical trial phases, Routes of administration
✍ Thomas Valère 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 1 views

Part I\*: Countries, Diseases, Clinical trial phases, Routes of administration ## Countries Countries where clinical trials are being performed or have been approved Gene therapy trials have now been initiated on all ®ve continents but the large majority of trials are being performed in the USA

A phase i clinical trial of didemnin B
A phase i clinical trial of didemnin B
✍ James A. Stewart; Jane B. Low; John D. Roberts; Alton Blow 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 448 KB 👁 1 views
A brief pain management program compared
A brief pain management program compared with physical therapy for low back pain: Results from an economic analysis alongside a randomized clinical trial
✍ Whitehurst, D. G. T. ;Lewis, M. ;Yao, G. L. ;Bryan, S. ;Raftery, J. P. ;Mullis, 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

## Abstract ## Objective Guidelines for the management of acute low back pain in primary care recommend early intervention to address psychosocial risk factors associated with long‐term disability. We assessed the cost utility and cost effectiveness of a brief pain management program (BPM) targeti

Outpatient combination chemoimmunotherap
Outpatient combination chemoimmunotherapy for patients with metastatic melanoma : Results of a Phase I/II trial
✍ Mohammed Kashani-Sabet; Richard W. Sagebiel; Henry E. Collins; Alan B. Glassberg 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## BACKGROUND. Few studies have examined the feasibility, safety, and efficacy of an outpatient biochemotherapy regimen of low dose, subcutaneously administered interleukin-2 (IL-2) for patients with metastatic (Stage IV) melanoma. ## METHODS. Nineteen patients were treated with intravenous cispl

Maxillary sinusitis as a surrogate model
Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies
✍ John A. Wagner; Ilynn B. Nepomuceno; Niraj Shah; Anna H. Messner; Mary Lynn Mora 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 475 KB 👁 2 views

Background Assessing the biological activity and clinical ef®cacy of gene therapy is critically important in cystic ®brosis (CF). It is widely accepted that clinical testing using surrogate markers including pulmonary function will be useful in assessing clinical ef®cacy. One problem with pulmonary